Tricuspid Stenosis Medication

  • Author: Mary C Mancini, MD, PhD; Chief Editor: Richard A Lange, MD   more...
 
Updated: Jul 1, 2011
 

Medication Summary

The goals of pharmacotherapy are to reduce morbidity and to prevent complications.

Next

Antiarrhythmic agents

Class Summary

Alter the electrophysiologic mechanisms responsible for arrhythmia.

View full drug information

Digoxin (Lanoxin)

 

Cardiac glycoside with direct inotropic effects and indirect effects on the cardiovascular system. Acts directly on cardiac muscle and increases myocardial systolic contractions. Indirect actions result in increased carotid sinus nerve activity and enhanced sympathetic withdrawal for any given increase in mean arterial pressure.

Previous
Next

Anticoagulants

Class Summary

Used for prophylaxis and treatment of venous thrombosis, pulmonary embolism, and thromboembolic disorders.

View full drug information

Warfarin (Coumadin)

 

Interferes with hepatic synthesis of vitamin K–dependent coagulation factors. Tailor dose to maintain an INR in the range of 2-3.

Previous
Proceed to Follow-up
 
 
Contributor Information and Disclosures
Author

Mary C Mancini, MD, PhD  Professor and Chief of Cardiothoracic Surgery, Department of Surgery, Louisiana State University School of Medicine in Shreveport

Mary C Mancini, MD, PhD is a member of the following medical societies: American Association for Thoracic Surgery, American College of Surgeons, American Surgical Association, Phi Beta Kappa, Society of Thoracic Surgeons, and Southern Surgical Association

Disclosure: Nothing to disclose.

Specialty Editor Board

Park W Willis IV, MD  Sarah Graham Distinguished Professor of Medicine and Pediatrics, University of North Carolina at Chapel Hill School of Medicine

Park W Willis IV, MD is a member of the following medical societies: American Society of Echocardiography

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Ronald J Oudiz, MD, FACP, FACC, FCCP  Professor of Medicine, University of California, Los Angeles, David Geffen School of Medicine; Director, Liu Center for Pulmonary Hypertension, Division of Cardiology, LA Biomedical Research Institute at Harbor-UCLA Medical Center

Ronald J Oudiz, MD, FACP, FACC, FCCP is a member of the following medical societies: American College of Cardiology, American College of Chest Physicians, American College of Physicians, American Heart Association, and American Thoracic Society

Disclosure: Actelion Grant/research funds Clinical Trials + honoraria; Encysive Grant/research funds Clinical Trials + honoraria; Gilead Grant/research funds Clinical Trials + honoraria; Pfizer Grant/research funds Clinical Trials + honoraria; United Therapeutics Grant/research funds Clinical Trials + honoraria; Lilly Grant/research funds Clinical Trials + honoraria; LungRx Clinical Trials + honoraria; Bayer Grant/research funds Consulting

Amer Suleman, MD  Private Practice

Amer Suleman, MD is a member of the following medical societies: American College of Physicians, American Heart Association, American Institute of Stress, American Society of Hypertension, Federation of American Societies for Experimental Biology, Royal Society of Medicine, and Society of Cardiac Angiography and Interventions

Disclosure: Nothing to disclose.

Chief Editor

Richard A Lange, MD  Professor and Executive Vice Chairman, Department of Medicine, Director, Office of Educational Programs, University of Texas Health Science Center at San Antonio

Richard A Lange, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Cardiology, American Heart Association, and Association of Subspecialty Professors

Disclosure: Nothing to disclose.

Acknowledgments

The authors and editors of eMedicine gratefully acknowledge the contributions of previous author Frank M Sheridan, MD to the development and writing of this article.

References

  1. Lev M, Liberthson RR, Joseph RH, Seten CE, Eckner FA, Kunske RD, et al. The pathologic anatomy of Ebstein's disease. Arch Pathol. Oct 1970;90(4):334-43. [Medline].

  2. Waller BF. Morphological aspects of valvular heart disease: Part I. Curr Probl Cardiol. Oct 1984;9(7):1-66. [Medline].

  3. Waller BF. Morphological aspects of valvular heart disease: Part II. Curr Probl Cardiol. Nov 1984;9(8):1-74. [Medline].

  4. Acikel M, Erol MK, Yekeler I, Ozyazicioglu A. A case of free-floating ball thrombus in right atrium with tricuspid stenosis. Int J Cardiol. Apr 2004;94(2-3):329-30. [Medline].

  5. Faletra F, La Marchesina U, Bragato R, De Chiara F. Three dimensional transthoracic echocardiography images of tricuspid stenosis. Heart. Apr 2005;91(4):499. [Medline].

  6. Roberts PA, Boudjemline Y, Cheatham JP, et al. Percutaneous Tricuspid Valve Replacement in Congenital and Acquired Heart Disease. JACC. 2011;58:117-22.

  7. Arnett EN, Roberts WC. Pathology of active infective endocarditis: a necropsy analysis of 192 patients. Thorac Cardiovasc Surg. Dec 1982;30(6):327-35. [Medline].

  8. Block PC, Bonhoeffer P. Percutaneous approaches to valvular heart disease. Curr Cardiol Rep. Mar 2005;7(2):108-13. [Medline].

  9. DiSesa VJ, Mills RM Jr, Collins JJ Jr. Surgical management of carcinoid heart disease. Chest. Nov 1985;88(5):789-91. [Medline].

  10. Kratz JM, Crawford FA Jr, Stroud MR, et al. Trends and results in tricuspid valve surgery. Chest. Dec 1985;88(6):837-40. [Medline].

  11. Miller BR, Vohr FH, Christian FV, Singh AK. Cardiac valvular replacement in carcinoid heart disease. Am J Med. Nov 1983;75(5):896-8. [Medline].

  12. Morgan JR, Forker AD, Coates JR, Myers WS. Isolated tricuspid stenosis. Circulation. Oct 1971;44(4):729-32. [Medline].

  13. Mukhopadhyay S, Suryavanshi S, Yusuf J, et al. Isolated thrombus producing tricuspid stenosis: an unusual presentation in primary antiphospholipid syndrome. Indian Heart J. Jan-Feb 2004;56(1):61-3. [Medline].

  14. Sakata Y, Koibuchi N, Xiang F, et al. The spectrum of cardiovascular anomalies in CHF1/Hey2 deficient mice reveals roles in endocardial cushion, myocardial and vascular maturation. J Mol Cell Cardiol. Oct 18 2005;[Medline].

  15. Sharieff S, Saghir T, Shah-e-Zaman K, et al. Concurrent percutaneous valvuloplasty of mitral and tricuspid valve stenoses. J Invasive Cardiol. Jun 2005;17(6):340-2. [Medline].

 
Previous
Next
 
A representation of a stenotic tricuspid valve. This image demonstrates fusion of the commissures (shown as dotted lines).
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.